Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JetBlue Airways Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while JetBlue Airways Corporation trades at $5.8 (market cap $2.19B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.5× JetBlue Airways Corporation's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JBLU | |
|---|---|---|
Market Cap | $29.60B | $2.19B |
Sector | Health | Industrials |
52-Week High | $491.22 | $6.46 |
52-Week Low | $205.48 | $4.03 |
Enterprise Value | $27.56B | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
JetBlue (JBLU) trades at $5.855, up 3.81% today, with a bullish technical signal from moving averages but mixed earnings history including a recent Q2 2026 beat. The company shows negative profitability with a net income margin of -9.32% and ROE of -44.36%, while valuation ratios like P/S of 0.23 suggest potential undervaluation. Recent news highlights analyst downgrades and operational challenges from high fuel costs, alongside strategic initiatives like new fare structures and lounge awards.
Outlook remains cautious due to persistent losses and external pressures, but cost management and revenue growth initiatives offer recovery potential. Key risks include fuel price volatility and competitive intensity, while analyst consensus is neutral with a $5.18 price target slightly below current levels, indicating limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
